Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose weekly erlotinib after progression on standard EGFR-TKI therapy in EGFR-mutated NSCLC
NL-OMON36916Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoints: Objective response rate at 8 weeks and Disease control rate at 8 weeks. Started Sep 2012; status: active, not recruiting.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36916.